Vectus Biosystems Ltd - Asset Resilience Ratio

Latest as of December 2023: 2.18%

Vectus Biosystems Ltd (VBS) has an Asset Resilience Ratio of 2.18% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check VBS strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

AU$70.00K
≈ $49.53K USD Cash + Short-term Investments

Total Assets

AU$3.21 Million
≈ $2.27 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2020)

This chart shows how Vectus Biosystems Ltd's Asset Resilience Ratio has changed over time. See Vectus Biosystems Ltd net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Vectus Biosystems Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Vectus Biosystems Ltd (VBS) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$70.00K 2.18%
Total Liquid Assets AU$70.00K 2.18%

Asset Resilience Insights

  • Limited Liquidity: Vectus Biosystems Ltd maintains only 2.18% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Vectus Biosystems Ltd Industry Peers by Asset Resilience Ratio

Compare Vectus Biosystems Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revolution Medicines Inc
NASDAQ:RVMD
Biotechnology 65.10%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Hugel Inc
KQ:145020
Biotechnology 29.57%
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Biotechnology 39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Absci Corp
NASDAQ:ABSI
Biotechnology 59.86%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%

Annual Asset Resilience Ratio for Vectus Biosystems Ltd (2013–2020)

The table below shows the annual Asset Resilience Ratio data for Vectus Biosystems Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2020-06-30 90.60% AU$2.72 Million
≈ $1.92 Million
AU$3.00 Million
≈ $2.12 Million
+4.48pp
2016-06-30 86.11% AU$4.03 Million
≈ $2.85 Million
AU$4.68 Million
≈ $3.31 Million
+85.82pp
2015-06-30 0.29% AU$33.99K
≈ $24.05K
AU$11.73 Million
≈ $8.30 Million
-77.53pp
2013-06-30 77.82% AU$1.16 Million
≈ $821.49K
AU$1.49 Million
≈ $1.06 Million
--
pp = percentage points

About Vectus Biosystems Ltd

AU:VBS Australia Biotechnology
Market Cap
$5.67 Million
AU$8.01 Million AUD
Market Cap Rank
#28321 Global
#1502 in Australia
Share Price
AU$0.15
Change (1 day)
+0.00%
52-Week Range
AU$0.04 - AU$0.44
All Time High
AU$2.00
About

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue t… Read more